Qunfeng Liang, MSc; Trasias Mukama, MPH, PhD; Kristina Sundquist, MD, PhD; et al.
JAMA Oncol. 2024;10(7):866-873. doi:10.1001/jamaoncol.2024.0827
This cohort study uses registry data to examine the risk of colorectal cancer (CRC) and CRC-specific death for up to 20 years after having a first colonoscopy with findings negative for CRC.
-
Editorial
The Interval for Screening Colonoscopy鈥擨s 15 the New 10?
Rashid N. Lui, MBChB; Andrew T. Chan, MD, MPH
JAMA Oncol
Omar El-Taji, MBChB, MRes; Samih Taktak, MBBS; Craig Jones, MBChB, MRes; et al.
JAMA Oncol. 2024;10(7):874-884. doi:10.1001/jamaoncol.2024.1549
This systematic review and meta-analysis investigates the incidence of cardiovascular events with addition of novel androgen receptor signaling inhibitors (ARSI) to standard of care in locally advanced and metastatic prostate cancer.
-
Invited Commentary
Cardiovascular Risk in Prostate Cancer鈥擜 Call to Action?
Katelyn M. Atkins, MD, PhD; Andriana P. Nikolova, MD, PhD
JAMA Oncol
Maureen E. Canavan, PhD; Xiaoliang Wang, PhD; Mustafa S. Ascha, PhD; et al.
open access
JAMA Oncol. 2024;10(7):887-895. doi:10.1001/jamaoncol.2024.1129
This cohort study evaluates whether the overall population of patients with metastatic cancer receiving care at practices with higher rates of oncologic therapy for very advanced disease experienced longer survival.
Nabil F. Saba, MD; Stuart J. Wong, MD; Tahseen Nasti, PhD; et al.
JAMA Oncol. 2024;10(7):896-904. doi:10.1001/jamaoncol.2024.1143
This nonrandomized controlled trial assessed the benefits and toxic effects of intensity-modulated reirradiation therapy with nivolumab in the treatment of patients with recurrent or second primary head and neck squamous cell carcinoma.
Manali I. Patel, MD, MPH, MS; Madhuri Agrawal, BS; Douglas W. Blayney, MD; et al.
JAMA Oncol. 2024;10(7):905-911. doi:10.1001/jamaoncol.2024.1221
This secondary analysis of data from the EPAC randomized clinical trial examines the association of a lay health worker鈥搇ed advance care planning intervention among patients with advanced stages of cancer with overall survival and end-of-life health care use and costs.
Victoria A. Sanchez, AuD, PhD; Paul C. Dinh Jr, PhD; Patrick O. Monahan, PhD; et al.
JAMA Oncol. 2024;10(7):912-922. doi:10.1001/jamaoncol.2024.1233
This cohort study evaluates cisplatin-related hearing loss with comprehensive audiologic assessments, assesses the longitudinal progression of cisplatin-related hearing loss, and identifies factors associated with risk.
Ari J. Rosenberg, MD; Nishant Agrawal, MD; Aditya Juloori, MD; et al.
JAMA Oncol. 2024;10(7):923-931. doi:10.1001/jamaoncol.2024.1530
This phase 2 nonrandomized clinical trial evaluates effectiveness and tolerance of neoadjuvant nivolumab, nab-paclitaxel, and carboplatin followed by response-adaptive therapy in patients with human papillomavirus鈭抪ositive oropharyngeal cancer.
Song Dong, PhD; Zhen Wang, PhD; Jia-Tao Zhang, PhD; et al.
open access
JAMA Oncol. 2024;10(7):932-940. doi:10.1001/jamaoncol.2024.1779
This nonrandomized controlled trial assesses the feasibility of using a circulating tumor DNA鈭抔uided adaptive de-escalation tyrosine kinase inhibitor strategy in patients with advanced non鈭抯mall cell lung cancer to achieve complete remission after local consolidative therapy.
Elysia K. Donovan, MD, MSc; Simon S. Lo, MBChB; Sushil Beriwal, MD, MBA; et al.
JAMA Oncol. 2024;10(7):941-948. doi:10.1001/jamaoncol.2024.1796
This cohort study evaluates the outcomes of stereotactic ablative radiotherapy in patients with oligometastatic and oligoprogressive gynecologic cancers.